• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of hepatic anti-fibrotic therapy targeted to angiotensin II receptor antagonist-soppression of collagen production in the Ito cell via TGF-β

Research Project

Project/Area Number 13557045
Research Category

Grant-in-Aid for Scientific Research (B)

Allocation TypeSingle-year Grants
Section展開研究
Research Field Gastroenterology
Research InstitutionYamagata University

Principal Investigator

KAWATA Sumio  Yamagata Univ. Medical Sch., Professor, 医学部, 教授 (90183285)

Co-Investigator(Kenkyū-buntansha) SAITO Koji  Yamagata Univ. Medical Sch., Assistant Prof., 医学部, 講師 (90250919)
SAITO Takafumi  Yamagata Univ. Medical Sch., Assistant Prof., 医学部, 講師 (80250918)
TOGASHI Hitoshi  Yamagata Univ. Medical Sch., Associate Prof., 医学部, 助教授 (60192209)
WATANABE Hisayoshi  Yamagata Univ. Medical Sch., Assistant, 医学部, 助手 (00332536)
Project Period (FY) 2001 – 2002
Project Status Completed (Fiscal Year 2002)
Budget Amount *help
¥6,500,000 (Direct Cost: ¥6,500,000)
Fiscal Year 2002: ¥2,800,000 (Direct Cost: ¥2,800,000)
Fiscal Year 2001: ¥3,700,000 (Direct Cost: ¥3,700,000)
KeywordsHepatic fibrosis / hepatic cirrhosis / chronic hepatitis C / Angiotensin II receptor / angiotensin II / 受容体阻害薬 / アンギオテンシンII / アンギオテンシンII受容体 / アンギオテンシン / アンギオテンシン受容体
Research Abstract

Anti-fibrotic therapy is expcted to prevent hepatic cirrhosis.
In 2001, we carried out a randomized controlled study on anti-fibrotic therapy for chronic hepatitis C without effect of interferon therapy. 30 consecutive patients with chronic hepatitis C were randomizedly divided into two groups. 15 patients were treated with losartan (50 mg/day), angiotensin II type 1 receptor antagonist, for 3 months. The other 15 patients were followed as controls. After the oral administration, plasma TGF-β1 concentrations, a marker of fibrosis, significantly decreased in the group of losartan whereas the concentrations did not change in the control group. Fibrosis area (%) in the losartan group was reduced with mild significance. This result suggested that blocking of angiotensin II signal leaded to suppression of heparic fibrosis.
In 2002, angiotensin II type 1 receptor antagonist (CS-866) was administered to rat cirrhosis model. The treated rats showed significant decrease in hepatic TGF-β1 and hydroxyproline contents. Histological examination revealed that degree of hepatic fibrosis was much lower in the treated than the controls.

Report

(3 results)
  • 2002 Annual Research Report   Final Research Report Summary
  • 2001 Annual Research Report
  • Research Products

    (12 results)

All Other

All Publications (12 results)

  • [Publications] Terui Y, Saito, T, Kawata S, et al.: "Effect of angiotensin receptor antagonist on liver fibrosis of chronic hepatitis C"Hepatology. 36(4). 1022 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Saito T, Shinzawa H, Kawata S, et al.: "Lamivadine and rapid regeneration of the atrophic liver in decompensated cirrhosis due to HBV"Am. J. Gastroenterol. 97. 493-494 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Saeki A, Tamura S, Kawata S, et al.: "Frequent impairment of the spindle assembly check point in hepatocellular carcinoma"Cancer. 94. 2047-2054 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Sakon M, Nagano H, Kawata S. et al.: "Combined intraarterial 5-FU and subcutanious IFN-α therapy for advanced hepatocellular carcinoma"Cancer. 94. 435-442 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Saito T, Shinzawa H, Kawata S, et al.: "Home lactulose enema : prevention of hepatic encephalopathy at home"J. Gastroenterol. 37. 68-69 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Aoki M, Saito T, Kawata S, et al.: "Clinical significance of a highly sensitive enzyme immunoassay of hepatitis B surface antigen"J. Med. Virol. 66. 166-170 (2002)

    • Related Report
      2002 Annual Research Report
  • [Publications] Terui Y., Kawata S., et al.: "Effect of angiotensin receptor antagonist on plasmic TGF-B1 levels and hepatis fibrosisin chronic hepatitis C"Hepatology. (印刷中).

    • Related Report
      2001 Annual Research Report
  • [Publications] Aoki M., Kawata S., et al.: "Clinical significance of a highly sensitive enzyme immunoassay of hepatitis B surface antigen"J.Med.Virol.. 66. 166-170 (2002)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kamada Y., Kawata S., et al.: "Vascular endothelial dysfunction resulting from L-anginine deficiency in lysinuric protein in tolerance"J.Clin.Invest. 108. 717-724 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kitada T., Kawata S., et al.: "The addition of bisecting N-acetylglucosamine residues to E-cadherin down regulates phosphonylation of B-catenin"J.Biol.Chem. 276. 475-480 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Tsushima H., Kawata S., et al.: "Circulating TGF-B1 as a predictor of liver metastasis after resection in colorectal cancer"Clin Cancer Res. 7. 1258-1262 (2001)

    • Related Report
      2001 Annual Research Report
  • [Publications] Kawata S., et al.: Brit J.Cancer. 84. 886-891 (2001)

    • Related Report
      2001 Annual Research Report

URL: 

Published: 2001-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi